Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Mark Rosenberg, MD, MPP, President of The Task Force for Global Health, former head of the National Center for Injury Prevention and Control, discusses the state of Centers of Disease Control and…
By Andrew M. Seaman New York (Reuters Health) – Women with lung cancer who ate the most soy before their diagnosis might live a little longer than those…
Sean Ahrens, co-founder of Crohnology, discusses how he brought a community of Crohn’s and Colitis patients together to share their collective knowledge and track their disease. Sean was diagnosed…
An estimated 20 to 40 percent of cancer patients receiving certain types of chemotherapy treatments may experience debilitating pain. The pain can cause a number of symptoms including…
NEW YORK (Reuters Health) – Environmental factors appear to influence the incidence of papillary thyroid microcarcinomas (PTMCs), according to a comparison of epidemiologic data from Sicily and the…
Mark Rosenberg, MD, MPP, President of The Task Force for Global Health, gives physicians tips on how they can play a role in reducing gun violence in their…
Rafael Yuste, MD, PhD, Professor of Neuroscience at Columbia University, discusses the many ways that the Brain Activity Map will fundamentally change medicine and neuroscience. Whether it’s pinpointing specific neural…
NEW YORK (Reuters Health) – In a randomized controlled trial, the anti-CA-125 vaccine abagovomab did not prolong survival in patients with ovarian cancer in first remission — despite…
What will it take to complete the Brain Activity Map? Rafael Yuste, MD, PhD, Professor of Neuroscience at Columbia University, talks about the latest tools being developed to measure…
NEW YORK (Reuters Health) – Even without conventional conditioning and cytoxic chemotherapy, an allogeneic hematopoietic cell transplant (HCT) can have a substantial benefit in patients with advanced hematologic…
